Gilead Sciences Inc (GILD)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.55 (-0.63%)Past Day

About

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Key Insights

  • Share Price

    $87.48

  • Market Cap

    $108.99 Billion

  • Total Outstanding Shares

    1.25 Billion Shares

  • Total Employees

    18,000

  • Dividend

    $0.77 Per Share Quarterly

  • IPO Date

    January 22, 1992

  • SIC Description

    Biological Products, (no Disgnostic Substances)

  • Homepage

    https://www.gilead.com

Historical Stock Splits

If you bought 1 share of GILD before September 7, 2004, you'd have 8 shares today.
Execution DateSplit Amount
January 28, 20132-for-1
June 25, 20072-for-1
September 7, 20042-for-1

Cash Flow Statement

April 1, 2024 to June 30, 2024
MetricValue
Net Cash Flow From Operating Activities$1.32 Billion
Net Cash Flow From Investing Activities, Continuing$-307.00 Million
Net Cash Flow$-1.95 Billion
Net Cash Flow From Investing Activities$-307.00 Million
Net Cash Flow From Financing Activities, Continuing$-2.95 Billion
Net Cash Flow From Financing Activities$-2.95 Billion
Net Cash Flow From Operating Activities, Continuing$1.32 Billion
Net Cash Flow, Continuing$-1.94 Billion
Exchange Gains/Losses$-11.00 Million

Income Statement

April 1, 2024 to June 30, 2024
MetricValue
Operating Expenses$2.77 Billion
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Selling, General, and Administrative Expenses$1.38 Billion
Net Income/Loss Attributable To Parent$1.61 Billion
Gross Profit$5.41 Billion
Cost Of Revenue$1.54 Billion
Revenues$6.95 Billion
Other Operating Expenses$1.39 Billion
Income Tax Expense/Benefit$438.00 Million
Net Income/Loss$1.61 Billion
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Net Income/Loss Available To Common Stockholders, Basic$1.61 Billion
Basic Earnings Per Share$1.29
Costs And Expenses$4.31 Billion
Income/Loss From Continuing Operations Before Tax$2.05 Billion
Income Tax Expense/Benefit, Deferred$-166.00 Million
Income/Loss From Continuing Operations After Tax$1.61 Billion
Benefits Costs and Expenses$4.90 Billion
Basic Average Shares$1.25 Billion
Diluted Average Shares$1.25 Billion
Operating Income/Loss$2.64 Billion
Nonoperating Income/Loss$-355.00 Million
Diluted Earnings Per Share$1.29
Preferred Stock Dividends And Other Adjustments$0.00

Balance Sheet

April 1, 2024 to June 30, 2024
MetricValue
Noncurrent Liabilities$24.60 Billion
Liabilities$35.38 Billion
Liabilities And Equity$53.58 Billion
Other Current Assets$10.29 Billion
Equity$18.20 Billion
Accounts Payable$537.00 Million
Other Current Liabilities$9.39 Billion
Intangible Assets$22.83 Billion
Other Non-current Liabilities$1.25 Billion
Fixed Assets$5.35 Billion
Noncurrent Assets$41.26 Billion
Equity Attributable To Noncontrolling Interest$-84.00 Million
Wages$852.00 Million
Current Liabilities$10.78 Billion
Long-term Debt$23.35 Billion
Inventory$2.03 Billion
Other Non-current Assets$13.08 Billion
Equity Attributable To Parent$18.28 Billion
Assets$53.58 Billion
Current Assets$12.32 Billion

Historical Dividends

Current dividend: $0.77 Per Share Quarterly
Announcement DatePayment DateRecord DateAmountFrequency
Aug 8, 2024Sep 27, 2024Sep 13, 2024$0.77Quarterly
Apr 25, 2024Jun 27, 2024Jun 14, 2024$0.77Quarterly
Feb 1, 2024Mar 28, 2024Mar 15, 2024$0.77Quarterly
Nov 7, 2023Dec 28, 2023Dec 15, 2023$0.75Quarterly
Aug 3, 2023Sep 28, 2023Sep 15, 2023$0.75Quarterly
Apr 27, 2023Jun 29, 2023Jun 15, 2023$0.75Quarterly
Feb 2, 2023Mar 30, 2023Mar 15, 2023$0.75Quarterly
Oct 27, 2022Dec 29, 2022Dec 15, 2022$0.73Quarterly
Aug 2, 2022Sep 29, 2022Sep 15, 2022$0.73Quarterly
Feb 1, 2022Mar 30, 2022Mar 15, 2022$0.73Quarterly
Oct 28, 2021Dec 30, 2021Dec 15, 2021$0.71Quarterly
Jul 29, 2021Sep 29, 2021Sep 15, 2021$0.71Quarterly
Apr 27, 2021Jun 29, 2021Jun 15, 2021$0.71Quarterly
Feb 4, 2021Mar 30, 2021Mar 15, 2021$0.71Quarterly
Oct 28, 2020Dec 30, 2020Dec 15, 2020$0.68Quarterly
Jul 30, 2020Sep 29, 2020Sep 15, 2020$0.68Quarterly
Apr 29, 2020Jun 29, 2020Jun 12, 2020$0.68Quarterly
Feb 3, 2020Mar 30, 2020Mar 13, 2020$0.68Quarterly
Oct 23, 2019Dec 30, 2019Dec 13, 2019$0.63Quarterly
Jul 29, 2019Sep 27, 2019Sep 13, 2019$0.63Quarterly
May 1, 2019Jun 27, 2019Jun 14, 2019$0.63Quarterly
Feb 1, 2019Mar 28, 2019Mar 15, 2019$0.63Quarterly
Oct 24, 2018Dec 28, 2018Dec 14, 2018$0.57Quarterly
Jul 24, 2018Sep 27, 2018Sep 14, 2018$0.57Quarterly
Apr 30, 2018Jun 28, 2018Jun 15, 2018$0.57Quarterly
Feb 5, 2018Mar 29, 2018Mar 16, 2018$0.57Quarterly
Oct 25, 2017Dec 28, 2017Dec 15, 2017$0.52Quarterly
Jul 25, 2017Sep 28, 2017Sep 15, 2017$0.52Quarterly
May 2, 2017Jun 29, 2017Jun 16, 2017$0.52Quarterly
Feb 6, 2017Mar 30, 2017Mar 16, 2017$0.52Quarterly
Nov 1, 2016Dec 29, 2016Dec 15, 2016$0.47Quarterly
Jul 22, 2016Sep 29, 2016Sep 16, 2016$0.47Quarterly
Apr 27, 2016Jun 29, 2016Jun 16, 2016$0.47Quarterly
Feb 2, 2016Mar 30, 2016Mar 16, 2016$0.43Quarterly
Oct 26, 2015Dec 30, 2015Dec 16, 2015$0.43Quarterly
Jul 23, 2015Sep 29, 2015Sep 16, 2015$0.43Quarterly
Apr 24, 2015Jun 29, 2015Jun 16, 2015$0.43Quarterly
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
News ArticlesAbout UsPrivacy Policy & Cookies Information

ⓒ2024 Financhle. All Rights Reserved.